Student, 22, brushed off common symptoms as a sinus infection before life-changing cancer diagnosis
A 22-year-old student is urging people to take their symptoms seriously after what she believed to be a simple sinus infection was actually cancer.
Breeze Hunter has revealed how she received the life-changing diagnosis after experiencing headaches for months on end, as well as persistent pressure in her nose.
She had shared her concerns with a medic, who informed her she had 'a lot of fluid' in her ears which was causing her headaches and that she likely had a 'sinus infection'.
When she headed back to the doctors a few months later still complaining of the continuing headaches as well as feeling 'very weak and fatigued', Breeze underwent some blood tests.
The Texas A&M University student was informed that she was very anaemic - meaning her body was not producing enough healthy red blood cells - which rang alarm bells, and she was encouraged to take herself to hospital.
Breeze headed to the University of Texas Medical Branch Hospital in her hometown of League City, Texas, and underwent further testing, where it emerged she was dealing with something a lot more sinister than a sinus infection.
"I had many people coming in and saying, 'It's looking like a sign of leukaemia, but we'll keep testing because it could be a bunch of other things'," she told Today.com.
"I freaked out. I had no idea what leukaemia was. I was like, 'am I going to survive this? Or is it treatable?'"
Her worst fears came true when doctors at the MD Anderson Cancer Center then confirmed she had acute myeloid leukaemia (AML), which the NHS describe as an 'aggressive cancer of the monocyte or granulocyte cells'.
It's considered a rare form of the disease, and around 3,100 people in the UK are diagnosed with it each year. Symptoms tend to progressively get worse.
Signs of AML can include looking pale or 'washed out', feeling tired or weak, breathlessness, frequent infections, unusual and frequent bruising or bleeding, and unexplained weight loss.
Breeze's treatment quickly got underway and she first had a bone marrow aspiration, a procedure where doctors take a sample of the liquid part of your bone marrow to be sent off for testing.
She also had a spinal tap, which is also known as a lumbar puncture, which is where a sample of cerebrospinal fluid is taken to be sent off for analysis.
Doctors determined it would be best for her to stay in hospital as they tackled the AML head on by giving her chemotherapy infusions, with a pill for a week straight as part of a clinical trial.
Medics saw a vast improvement in her health within 21 days, and Breeze was given a second round of the trial treatment.
"I was supposed to get at least six rounds," the college student said. "The chemo worked so well I only had to do two."
After 11 rounds of radiation and another blast of chemotherapy, Breeze then underwent a stem cell transplant. Thankfully, her younger brother Roy, 21, was a perfect match and was able to be her donor.
Reflecting on her intense treatment, the young woman explained: "I got a radiation/chemo burn all over my body, which was very very painful and I was pretty much burnt all over.
"Probably towards the end, I was over it. I was like, 'I can't do this. This is too much'. It was very hard at times but God's watching me. So, I knew I was going to be okay."
Breeze remained in hospital for over a month as she recovered.
Dr Courtney DiNardo, a professor at The University of Texas MD Anderson Cancer Center with an expertise in of leukaemia, said Breeze is now 'doing fantastic'.
"Being a college student in the prime of your life getting dealt a life-threatening cancer diagnosis, I can only imagine how life altering and depressing it could be," he said.
"But she's always had such a beautiful spirit and good attitude."
Breeze will continue with chemotherapy treatment for the next year to be on the safe side - but says she is 'so excited' to make the most of her second chance at life.
"Cancer is very, very scary," the student said. "If you ever have any side effects like headaches, you're losing weight, you have bruises on you, anything like that, go to the doctor and get blood work done...it can't hurt you and it just tells you if something is wrong."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 hours ago
- Yahoo
A&M gets new Dean of Veterinary Medicine and Biomed Science
College Station, Tx (FOX 44) – Texas A&M University has appointed Dr. Bonnie R. Rush as the next dean of the College of Veterinary Medicine and Biomedical Sciences. Dr. Rush comes from a position as the Hodes Family Dean of the College of Veterinary Medicine at Kansas State University, where she has served for over thirty years, She begins her new job at A&M August 1. 'Dr. Rush brings to Texas A&M an extraordinary record of academic leadership, clinical insight and institutional vision,' said Dr. Alan Sams, executive vice president and provost. 'Her commitment to innovation, wellness and student success aligns perfectly with the mission of the university and the VMBS. I'm confident she will elevate the impact of our veterinary programs across Texas and beyond.' Rush joined Kansas State's faculty in 1993 as an associate professor of equine internal medicine and rose through the ranks to department head, then hospital director and, in 2017, to dean. She is a Diplomate of the American College of Veterinary Internal Medicine (Large Animal) and an internationally respected voice in veterinary internal medicine, medical education and student well-being. During her tenure as dean, she led the creation of multiple Doctor of Veterinary Medicine (DVM) certificate programs and expanded clinical outreach through high-impact shelter medicine and community rotations. She also launched a donor-funded student wellness program — now a national model for veterinary schools — and oversaw major faculty and staff development initiatives, as well as the renovation of teaching and hospital facilities. Her leadership helped secure federal funding from the National Institutes of Health to support a new biomedical research facility on the Kansas State campus. Rush currently serves as president of the American Association of Veterinary Medical Colleges, a role that gives her a national platform to address the future of veterinary education and workforce development. Rush currently serves as president of the American Association of Veterinary Medical Colleges, a role that gives her a national platform to address the future of veterinary education and workforce development.'I'm deeply honored to join Texas A&M and lead a college with such a distinguished legacy in veterinary medicine, biomedical sciences and One Health research,' Rush said. 'The faculty, staff and students at VMBS are at the forefront of the profession, and I'm excited to partner with them to advance education, research and service in ways that truly matter to animals, people and communities.' Rush earned her Doctor of Veterinary Medicine degree, summa cum laude, and a Master of Science in Veterinary Clinical Sciences from The Ohio State University. Her scholarship has focused on respiratory disease in horses, as well as evidence-based approaches to clinical teaching. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
a day ago
- Yahoo
Johnson & Johnson announces new Phase 1b data on bleximenib
Johnson & Johnson announced new Phase 1b data showing antileukemic activity and a safety profile for bleximenib in combination with venetoclax and azacitidine for the treatment of acute myeloid leukemia harboring KMT2A gene rearrangements or NPM1 gene mutations. The study evaluated patients with newly diagnosed, intensive chemo-ineligible AML and relapsed or refractory AML. The results were featured in an oral presentation at the 2025 European Hematology Association Congress. Even though AML is the most common type of acute leukemia in adults, it has the lowest survival rate and is associated with poor patient outcomes, despite treatment advances to date – especially for patients with KMT2Ar and NPM1m. The Phase 1b dose-finding study evaluated 125 patients with relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML who harbored KMT2Ar or NPM1m. Bleximenib in combination with VEN + AZA was evaluated across multiple dose levels without step-up dosing. Of the 85 relapsed or refractory patients, 36 percent received one, 42 percent received two and 12 percent received three lines of prior treatment; 47 percent had previously been treated with venetoclax. The bleximenib data at 100 mg twice a day in combination with VEN + AZA showed higher efficacy and a similar safety profile in comparison to other dose levels. At the recommended Phase 2 dose, patients with relapsed or refractory AML achieved an overall response rate of 82 percent and a composite complete response rate of 59 percent. The newly diagnosed, intensive chemo-ineligible patient population showed an ORR of 90 percent and a cCR rate of 75 percent. Safety analysis of the study population showed a profile comparable among dose groups, genetic subtypes and disease settings. At the RP2D in combination with VEN+AZA, differentiation syndrome events were reported in two of 49 patients. Bleximenib safety data continued to support a lack of QTc prolongation signal, with no events of Grade 3 or higher and only three Grade 1 events at the RP2D. The most common all-grade treatment-emergent adverse events were nausea, thrombocytopenia, neutropenia and anemia. The most common Grade 3 or higher TEAEs were thrombocytopenia, neutropenia, and anemia. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on JNJ: Disclaimer & DisclosureReport an Issue RFK Jr. names eight members to vaccine panel, WSJ reports RFK Jr. names new CDC vaccine advisory panel picks, STAT reports Johnson & Johnson reports results from Phase 3b APEX study on TREMFYA Johnson & Johnson Elects Daniel Pinto to Board Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
Yahoo
a day ago
- Yahoo
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib REDWOOD CITY, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ('Biomea' or the 'Company') (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced updated preliminary clinical data from the ongoing Phase I COVALENT-103 trial of BMF-500 in adults with relapsed or refractory ('R/R') acute leukemia ('AL'). The results will be presented in a poster presentation at the European Hematology Association ('EHA') 2025 Congress in Milan, Italy. The presentation by Dr. Farhad Ravandi of The University of Texas MD Anderson Cancer Center will highlight emerging safety, pharmacokinetics/pharmacodynamics, and early clinical activity data for BMF-500, a highly selective covalent FMS-like tyrosine kinase 3 ('FLT3') inhibitor, in heavily pretreated patients with R/R AL. Key Results from the EHA 2025 Poster Presentation27 patients were enrolled across two study arms, Arm A (no CYP3A4 inhibitor; n=10) and Arm B (CYP3A4 inhibitor; n=17). All patients had R/R AL, with a median of 4 prior lines of therapy. 18 of the 27 patients were FLT3 mutations ('FLT3m') while the other 9 patients had FLT3 wild-type AL. Frequent co-mutations included WT1, TP53, IDH1/2, and NRAS. All 18 FLT3m patients had failed gilteritinib in the R/R setting and 9 of the 18 had received at least two FLT3 inhibitors prior to study entry. 26 of 27 (96%) enrolled patients had also received and failed the BCL2 inhibitor venetoclax. Key findings include: Clinical Activity Observed: 9 of 11 efficacy-evaluable FLT3m patients, defined as all patients enrolled who received at least one dose and had at least one disease assessment, showed bone marrow (BM) blast reduction; 5 of 11 achieved >50% BM blast reduction. 1 FLT3m patient achieved complete remission with incomplete hematologic recovery (CRi), sustained for 6 cycles. 1 FLT3m patient achieved morphologic leukemia-free state (MLFS); response is ongoing. 1 FLT3m patient met all criteria for partial response (PR) except platelet recovery; categorized as near PR. 2 of 4 efficacy-evaluable FLT3 wild-type patients achieved durable disease control ≥120 days, with treatment ongoing for one patient. Additional clinical improvements include reductions in peripheral blasts, transfusion dependency, and frequency of hydroxyurea use. Pharmacokinetics/Pharmacodynamics: FLT3 inhibition correlated with BMF-500 systemic exposures. Bone marrow and plasma concentrations of BMF-500 and its metabolites were comparable, suggesting good compartmental penetration. Survival: Median overall survival (mOS) among all treated FLT3m patients (n=18) was 3.8 months (Arm A) and 3.5 months (Arm B) during dose escalation. For the efficacy-evaluable FLT3m patients (n=12), the mOS for Arms A and B was 3.8 and 3.6 months, respectively during dose escalation. These survival durations compare favorably to historical mOS of 2.1 months in patients with R/R FLT3m acute myeloid leukemia ('AML') post-failure with both gilteritinib and venetoclax. 1 Ongoing Dose Escalation: Dose escalation continues at 200 mg BID (Arm A) and 75 mg BID (Arm B). Based on observed activity and tolerability, further evaluation is underway to determine optimal biologic dose ('OBD') and recommended Phase II dose ('RP2D'). Safety and Tolerability BMF-500 was generally well-tolerated across dose levels. No dose-limiting toxicities (DLTs), QT prolongation, or discontinuations due to treatment-related adverse events were reported. Escalation is ongoing without safety restrictions. 'The updated COVALENT-103 results continue to support the potential of BMF-500 as a selective, covalent FLT3 inhibitor,' said Mick Hitchcock, Ph.D., Interim Chief Executive Officer of Biomea Fusion. 'We are encouraged by the depth of bone marrow responses, the achievement of MLFS and CRi, and the early survival benefit in heavily pretreated patients with FLT3 mutations who had progressed following prior FLT3 inhibitor therapy. These data speak to BMF-500's potential to meaningfully improve outcomes in a high-risk AML population with no currently available treatment options.' Following completion of the COVALENT-103 dose escalation phase in R/R AL patients with FLT3m, Biomea plans to conclude its internal development of BMF-500 in oncology and is actively exploring strategic partnerships to advance the program. Poster Presentation Details Date/Time: Saturday, June 14 (18:30-19:30 CEST) Title: Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the COVALENT-103 Study (NCT05918692) Poster Number: PS1520 Presenter: Farhad Ravandi, M.D., University of Texas MD Anderson Cancer Center About COVALENT-103 COVALENT-103 is a multicenter, open-label, non-randomized trial seeking to evaluate the safety and efficacy of BMF-500, a twice daily oral treatment, in adult patients with R/R AL with FLT3 wild-type or FLT3m. The Phase I COVALENT-103 study aims to evaluate the safety and tolerability of BMF-500, determine the optimal biologic dose and recommended Phase II dose, and identify initial efficacy signals. Additional information about the Phase I clinical trial of BMF-500 can be found at using the identifier, NCT05918692. About BMF-500 BMF-500 is an investigational, orally bioavailable, covalent small molecule inhibitor of FLT3, discovered in-house using Biomea's proprietary FUSION™ System. Designed to be highly potent and selective, BMF-500 has demonstrated encouraging potential in extensive preclinical studies. Its kinase inhibitory profile indicates strong target selectivity, which may translate to a reduced risk of off-target effects. About Biomea FusionBiomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both designed to significantly improve the lives of patients with diabetes, obesity, and other metabolic diseases. We aim to cure. Visit us at and follow us on LinkedIn, X, and Facebook. Forward-Looking Statements Statements we make in this press release may include statements which are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development programs, including BMF-500, the potential of BMF-500 as a treatment for patients with FLT3m R/R AL, our research, development, partnership and regulatory plans, and the timing of such events may be deemed to be forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including the risk that preliminary or interim results of preclinical studies or clinical trials may not be predictive of future or final results in connection with future clinical trials and the risk that we may encounter delays in preclinical or clinical development, patient enrollment and in the initiation, conduct and completion of our ongoing and planned clinical trials and other research and development activities. These risks concerning Biomea's business and operations are described in additional detail in its periodic filings with the U.S. Securities and Exchange Commission (SEC), including its most recent periodic report filed with the SEC and subsequent filings thereafter. Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Reference: 1. Corley et al. (P1798) HemaSphere 2024;8(S1), 3339-3340. Contact: Meichiel Jennifer Weiss Sr. Director, Investor Relations and Corporate DevelopmentIR@